Your browser is no longer supported. Please, upgrade your browser.
Daxor Corporation
Index- P/E- EPS (ttm)-0.45 Insider Own4.10% Shs Outstand3.98M Perf Week-3.23%
Market Cap36.54M Forward P/E- EPS next Y- Insider Trans3.22% Shs Float1.31M Perf Month-15.79%
Income-1.70M PEG- EPS next Q- Inst Own5.00% Short Float1.05% Perf Quarter-7.41%
Sales0.30M P/S121.80 EPS this Y-227.50% Inst Trans- Short Ratio0.45 Perf Half Y-31.35%
Book/sh3.94 P/B2.28 EPS next Y- ROA-10.70% Target Price- Perf Year-50.00%
Cash/sh0.00 P/C- EPS next 5Y- ROE-12.80% 52W Range8.58 - 18.37 Perf YTD-28.00%
Dividend- P/FCF- EPS past 5Y28.80% ROI-2.80% 52W High-51.01% Beta-1.10
Dividend %- Quick Ratio- Sales past 5Y-24.10% Gross Margin- 52W Low4.89% ATR0.82
Employees37 Current Ratio- Sales Q/Q-50.00% Oper. Margin- RSI (14)38.30 Volatility7.61% 8.97%
OptionableNo Debt/Eq0.01 EPS Q/Q830.20% Profit Margin- Rel Volume0.76 Prev Close9.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume30.67K Price9.00
Recom2.00 SMA20-8.95% SMA50-15.12% SMA200-25.59% Volume0 Change0.00%
May-16-19Initiated Ascendiant Capital Markets Buy $20
Aug-04-21 08:30AM  
Jul-22-21 08:30AM  
Jul-13-21 08:30AM  
May-28-21 08:30AM  
May-27-21 07:15PM  
May-13-21 08:30AM  
May-06-21 08:30AM  
Apr-29-21 08:31AM  
Mar-25-21 11:25AM  
Mar-18-21 08:30AM  
Mar-16-21 08:30AM  
Mar-15-21 08:30AM  
Mar-04-21 08:30AM  
Feb-27-21 02:39AM  
Feb-26-21 08:30AM  
Feb-19-21 08:30AM  
Feb-05-21 08:30AM  
Feb-04-21 08:30AM  
Jan-26-21 08:30AM  
Jan-13-21 08:30AM  
Jan-08-21 08:30AM  
Dec-10-20 08:30AM  
Dec-09-20 08:30AM  
Nov-19-20 08:30AM  
Oct-29-20 08:30AM  
Oct-12-20 08:30AM  
Oct-08-20 03:30PM  
Oct-06-20 08:30AM  
Oct-05-20 08:30AM  
Oct-02-20 08:30AM  
Sep-28-20 08:57AM  
Sep-15-20 08:30AM  
Sep-10-20 08:30AM  
Aug-31-20 08:30AM  
Aug-24-20 08:30AM  
Aug-04-20 08:00AM  
Jul-20-20 09:09AM  
Jul-16-20 03:41PM  
Jul-15-20 08:00AM  
Jul-08-20 08:00AM  
Jun-30-20 08:00AM  
May-29-20 03:34PM  
May-26-20 04:50PM  
May-22-20 08:00AM  
Apr-23-20 08:30AM  
Mar-20-20 08:00AM  
Mar-09-20 08:30AM  
Mar-06-20 08:00AM  
Mar-04-20 09:48AM  
Mar-03-20 09:23AM  
Mar-02-20 08:00AM  
Feb-20-20 08:30AM  
Feb-12-20 08:00AM  
Dec-31-19 11:20AM  
Nov-21-19 08:00AM  
Nov-12-19 08:00AM  
Oct-29-19 07:37AM  
Oct-15-19 08:00AM  
Oct-10-19 08:30AM  
Sep-24-19 08:00AM  
Sep-19-19 10:15AM  
Sep-18-19 08:00AM  
Sep-11-19 08:00AM  
Sep-04-19 08:00AM  
Aug-30-19 08:59AM  
Aug-06-19 08:00AM  
Jun-18-19 08:00AM  
May-31-19 08:00AM  
May-30-19 08:00AM  
May-27-19 11:28AM  
Mar-21-19 08:30AM  
Mar-15-19 08:30AM  
Mar-04-19 08:30AM  
Feb-22-19 08:37AM  
Feb-13-19 08:30AM  
Jan-23-19 08:30AM  
Jan-10-19 08:30AM  
Nov-13-18 08:30AM  
Nov-08-18 01:46PM  
Nov-07-18 08:30AM  
Nov-01-18 08:30AM  
Oct-31-18 08:00AM  
Oct-30-18 08:30AM  
Sep-28-18 08:30AM  
Sep-25-18 08:30AM  
Sep-17-18 08:30AM  
Sep-12-18 08:30AM  
Aug-24-18 08:30AM  
Aug-20-18 08:30AM  
Jun-29-18 07:20AM  
Jun-12-18 08:30AM  
Jun-04-18 08:30AM  
May-30-18 08:30AM  
May-29-18 08:30AM  
May-16-18 07:47PM  
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Michel Robert JCHIEF FINANCIAL OFFICERApr 19Buy10.251,00010,2504,250Apr 19 03:14 PM
Feldschuh Michael RichardCEO & PresidentApr 16Buy10.334,20043,386158,206Apr 16 09:45 PM